BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Clinical Outcome
6 results:

  • 1. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
    van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
    Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
    Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
    Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant prostate cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Advanced prostate cancer with atm Loss: PARP and ATR Inhibitors.
    Neeb A; Herranz N; Arce-Gallego S; Miranda S; Buroni L; Yuan W; Athie A; Casals T; Carmichael J; Rodrigues DN; Gurel B; Rescigno P; Rekowski J; Welti J; Riisnaes R; Gil V; Ning J; Wagner V; Casanova-Salas I; Cordoba S; Castro N; Fenor de la Maza MD; Seed G; Chandran K; Ferreira A; Figueiredo I; Bertan C; Bianchini D; Aversa C; Paschalis A; Gonzalez M; Morales-Barrera R; Suarez C; Carles J; Swain A; Sharp A; Gil J; Serra V; Lord C; Carreira S; Mateo J; de Bono JS
    Eur Urol; 2021 Feb; 79(2):200-211. PubMed ID: 33176972
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in prostate cancer.
    Paschalis A; Sheehan B; Riisnaes R; Rodrigues DN; Gurel B; Bertan C; Ferreira A; Lambros MBK; Seed G; Yuan W; Dolling D; Welti JC; Neeb A; Sumanasuriya S; Rescigno P; Bianchini D; Tunariu N; Carreira S; Sharp A; Oyen W; de Bono JS
    Eur Urol; 2019 Oct; 76(4):469-478. PubMed ID: 31345636
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
    Lipton A; Cook R; Saad F; Major P; Garnero P; Terpos E; Brown JE; Coleman RE
    Cancer; 2008 Jul; 113(1):193-201. PubMed ID: 18459173
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.